MX2021010857A - Anticuerpos biespecificos anti-v(beta17)/anti-cd123. - Google Patents
Anticuerpos biespecificos anti-v(beta17)/anti-cd123.Info
- Publication number
- MX2021010857A MX2021010857A MX2021010857A MX2021010857A MX2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A
- Authority
- MX
- Mexico
- Prior art keywords
- bispecific antibodies
- beta17
- antibodies
- kasumi
- pathologies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816464P | 2019-03-11 | 2019-03-11 | |
| PCT/IB2020/000342 WO2020183245A2 (en) | 2019-03-11 | 2020-03-11 | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010857A true MX2021010857A (es) | 2021-12-15 |
Family
ID=71670296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010857A MX2021010857A (es) | 2019-03-11 | 2020-03-11 | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12264197B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3937977A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7566766B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210138033A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119954959A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020235475B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021017801A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132916A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286147A (cg-RX-API-DMAC7.html) |
| MA (1) | MA55305A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021010857A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020183245A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| IL300505A (en) * | 2020-08-10 | 2023-04-01 | Janssen Biotech Inc | Materials and methods for the production of biologically engineered virus-specific lymphocytes |
| IL301242A (en) * | 2020-09-11 | 2023-05-01 | Janssen Biotech Inc | Multi-specific immune targeting molecules and uses thereof |
| UY39415A (es) * | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Métodos y composiciones para modular la inmunidad mediada por cadenas beta |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| TWI815194B (zh) * | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4426734A1 (en) * | 2021-11-01 | 2024-09-11 | Janssen Biotech, Inc. | Compositions and methods for the modulation of beta chain-mediated immunity |
| AU2023217968A1 (en) * | 2022-02-09 | 2024-09-26 | Janssen Biotech, Inc. | Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes |
| AU2024217296A1 (en) * | 2023-02-09 | 2025-09-25 | Janssen Biotech, Inc. | Anti-v beta 17/anti-cd123 bispecific antibodies |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| US6413516B1 (en) | 1989-03-21 | 2002-07-02 | The Immune Response Corporation | Peptides and methods against psoriasis |
| FR2681875A1 (fr) | 1991-09-26 | 1993-04-02 | Immunotech Sa | Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| US6084087A (en) * | 1991-09-27 | 2000-07-04 | New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery | DNA encoding conserved T-cell receptor sequences |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| ES2243007T3 (es) | 1997-09-16 | 2005-11-16 | Egea Biosciences Llc | Sintesis quimica completa y sintesis de genes de genomas. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| TW200724548A (en) | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| WO2009139822A1 (en) | 2008-05-01 | 2009-11-19 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| US20110097339A1 (en) | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| EP2819695B1 (en) * | 2012-03-02 | 2018-06-27 | Academia Sinica | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF |
| US9790274B2 (en) | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| DK3189081T3 (da) * | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| US10556959B2 (en) | 2014-11-07 | 2020-02-11 | Xencor, Inc. | Anti-CD39 antibodies and uses thereof |
| WO2016167306A1 (ja) | 2015-04-16 | 2016-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ヒトNotch4抗体 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
| JP7252627B2 (ja) * | 2016-12-15 | 2023-04-05 | デューク ユニバーシティ | 制御性b10細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用 |
| US11370830B2 (en) | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
| EP3630839A1 (en) * | 2017-06-01 | 2020-04-08 | Xencor, Inc. | Bispecific antibodies that bind cd 123 cd3 |
| US12564632B2 (en) | 2017-11-08 | 2026-03-03 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7700039B2 (ja) | 2019-01-04 | 2025-06-30 | マレンゴ・セラピューティクス,インコーポレーテッド | 抗tcr抗体分子およびその使用 |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| CA3143995A1 (en) | 2019-06-21 | 2020-12-24 | Single Cell Technology, Inc. | Anti-tigit antibodies |
| WO2021064671A1 (en) | 2019-10-03 | 2021-04-08 | Janssen Biotech, Inc. | Methods for producing biotherapeutics with increased stability by sequence optimization |
| CA3173268A1 (en) | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| UY39415A (es) | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Métodos y composiciones para modular la inmunidad mediada por cadenas beta |
| IL301242A (en) | 2020-09-11 | 2023-05-01 | Janssen Biotech Inc | Multi-specific immune targeting molecules and uses thereof |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
-
2020
- 2020-03-11 CN CN202510015884.6A patent/CN119954959A/zh active Pending
- 2020-03-11 CN CN202080034083.XA patent/CN113874400B/zh active Active
- 2020-03-11 CA CA3132916A patent/CA3132916A1/en active Pending
- 2020-03-11 WO PCT/IB2020/000342 patent/WO2020183245A2/en not_active Ceased
- 2020-03-11 JP JP2021553382A patent/JP7566766B2/ja active Active
- 2020-03-11 EP EP20742831.9A patent/EP3937977A2/en active Pending
- 2020-03-11 US US17/437,771 patent/US12264197B2/en active Active
- 2020-03-11 KR KR1020217031687A patent/KR20210138033A/ko active Pending
- 2020-03-11 AU AU2020235475A patent/AU2020235475B2/en active Active
- 2020-03-11 MX MX2021010857A patent/MX2021010857A/es unknown
- 2020-03-11 BR BR112021017801A patent/BR112021017801A2/pt unknown
- 2020-03-11 MA MA055305A patent/MA55305A/fr unknown
-
2021
- 2021-09-05 IL IL286147A patent/IL286147A/en unknown
-
2024
- 2024-08-13 JP JP2024135000A patent/JP2024170426A/ja active Pending
-
2025
- 2025-02-24 US US19/061,801 patent/US20250257132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020235475A1 (en) | 2021-09-30 |
| BR112021017801A2 (pt) | 2022-01-18 |
| CN113874400B (zh) | 2025-02-07 |
| WO2020183245A2 (en) | 2020-09-17 |
| CN119954959A (zh) | 2025-05-09 |
| US20250257132A1 (en) | 2025-08-14 |
| AU2020235475B2 (en) | 2026-07-16 |
| IL286147A (en) | 2021-10-31 |
| US12264197B2 (en) | 2025-04-01 |
| WO2020183245A3 (en) | 2020-12-03 |
| KR20210138033A (ko) | 2021-11-18 |
| MA55305A (fr) | 2022-01-19 |
| US20220127359A1 (en) | 2022-04-28 |
| CN113874400A (zh) | 2021-12-31 |
| JP2024170426A (ja) | 2024-12-10 |
| JP2022523442A (ja) | 2022-04-22 |
| JP7566766B2 (ja) | 2024-10-15 |
| CA3132916A1 (en) | 2020-09-17 |
| EP3937977A2 (en) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020183245A3 (en) | Anti-v(beta17)/anti-cd123 bispecific antibodies | |
| ZA202102549B (en) | Substituted tolyl as fungicides | |
| IL290267A (en) | Bispecific antibodies are directed against cd3 | |
| IL292727A (en) | Multispecific antibodies | |
| CL2020000595S1 (es) | Estuche de auriculares. | |
| WO2020061478A3 (en) | Methods for purifying heterodimeric, multispecific antibodies | |
| IL277072A (en) | Anti-claudin antibodies 18.2 | |
| GEP20227403B (en) | Compounds | |
| WO2020047007A3 (en) | Methods for generating spatially barcoded arrays | |
| CA228332S (en) | Motorcycle | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| CL2020000174S1 (es) | Automóvil. | |
| MX385456B (es) | Anticuerpos cd123 y conjugados de los mismos. | |
| PH12021551860A1 (en) | Ltbp complex-specific inhibitors of tgfã and uses thereof | |
| MX383917B (es) | Nuevos péptidos que se unen al ligando-1 de muerte programada (pd-l1) para formación de imagen. | |
| CL2019002232S1 (es) | Automóvil. | |
| MX2020014097A (es) | Lipidos novedosos. | |
| CL2020001201S1 (es) | Automóvil. | |
| IL276211A (en) | HU14.18K322A monoclonal antibody production process | |
| MX2021000797A (es) | Anticuerpos agonistas de cd226. | |
| JOP20200295A1 (ar) | أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها | |
| IL286757A (en) | Antibodies in specific | |
| CA218448S (en) | Frame for cycle | |
| MX2025011053A (es) | Anticuerpos multiespecificos cd19/cd38 |